Asymmetry Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Asymmetry Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$14.8M	Buy	137,610 +112,661	+452%	+$12.3M	7.87%	2
2021 Q3	$2.73M	Buy	+24,949	New	+$2.59M	1.64%	23
2020 Q4	–	Sell	-51,995	Closed	-$4.04M	–	48
2020 Q3	$4.04M	Buy	+51,995	New	+$3.58M	2.6%	17

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Asymmetry Capital Management's HZNP Position: Q4 2021 in Review

Asymmetry Capital Management increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 452% in Q4 2021, buying an estimated $12.3M and bringing the position to 137,610 shares worth $14.8M. The position accounts for 7.87% of the portfolio, ranked #2.

Asymmetry Capital Management first reported a position in HZNP in Q3 2020 and has held it in 3 quarters since. 611 funds tracked by Wall St. Rank hold HZNP as of Q4 2021.

Asymmetry Capital Management held 137,610 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $14.8M as of Q4 2021.
Asymmetry Capital Management bought 112,661 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2021, an estimated $12.3M.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 7.87% of Asymmetry Capital Management's portfolio in Q4 2021, its #2 holding.
Asymmetry Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and has held it in 3 quarters since.
611 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.